Neurocrine Bio. (NBIX) PT Lowered to $173 at Morgan Stanley
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $165.11 +6.63%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $173.00 (from $178.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Sony Financial Holdings (8729:JP) (SNYFY) PT Lowered to JPY180 at Nomura/Instinet
- Suntory Beverage & Food Ltd (2587:JP) (STBFY) PT Lowered to JPY4,600 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
